{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:27:22Z","timestamp":1786598842629,"version":"build-2736575974"},"reference-count":282,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Central South University Graduate Student Research and Innovation Project","award":["No. 1053320240167"],"award-info":[{"award-number":["No. 1053320240167"]}]},{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["No. 2024JJ6684"],"award-info":[{"award-number":["No. 2024JJ6684"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Youth Science Foundation of Xiangya Hospital","award":["No. 2023Q20"],"award-info":[{"award-number":["No. 2023Q20"]}]},{"name":"the Natural Science Foundation of Changsha","award":["No.kq2403025"],"award-info":[{"award-number":["No.kq2403025"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Nos.82504074"],"award-info":[{"award-number":["Nos.82504074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82573819"],"award-info":[{"award-number":["No. 82573819"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the key Program of National Natural Science Foundation of China","award":["U22A20329"],"award-info":[{"award-number":["U22A20329"]}]},{"name":"Central South University Research Programme of Advanced Interdisciplinary Studies","award":["2023QYJC004"],"award-info":[{"award-number":["2023QYJC004"]}]},{"name":"the Scientific Research Program of FuRong Laboratory","award":["No. 2023SK2095"],"award-info":[{"award-number":["No. 2023SK2095"]}]},{"name":"the Natural Science Foundation of Hunan Province for Distinguished Young Scholars","award":["No. 2023JJ10096"],"award-info":[{"award-number":["No. 2023JJ10096"]}]},{"name":"Innovation Research Group Project of the National Natural Science Foundation of China","award":["No. 82221002"],"award-info":[{"award-number":["No. 82221002"]}]},{"name":"the Key Program of National Natural Science Foundation of China","award":["No. 82130090"],"award-info":[{"award-number":["No. 82130090"]}]},{"name":"Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China","award":["JYB2025XDXM603"],"award-info":[{"award-number":["JYB2025XDXM603"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02694-7","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:24:42Z","timestamp":1780669482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation"],"prefix":"10.1186","volume":"25","author":[{"given":"Qingyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanlin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2694_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366\u201379. https:\/\/doi.org\/10.1080\/15384047.2019.1640032.","journal-title":"Cancer Biol Ther"},{"key":"2694_CR2","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043. https:\/\/doi.org\/10.3322\/caac.70043.","journal-title":"CA Cancer J Clin"},{"key":"2694_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.clindermatol.2012.08.015","volume":"31","author":"C Lee","year":"2013","unstructured":"Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. Clin Dermatol. 2013;31:141\u20137. https:\/\/doi.org\/10.1016\/j.clindermatol.2012.08.015.","journal-title":"Clin Dermatol"},{"key":"2694_CR4","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.Can-07-6611","volume":"68","author":"VT DeVita Jr.","year":"2008","unstructured":"DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u201353. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6611.","journal-title":"Cancer Res"},{"key":"2694_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CMR.0b013e328351fa4d","volume":"22","author":"VW Rebecca","year":"2012","unstructured":"Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012;22:114\u201322. https:\/\/doi.org\/10.1097\/CMR.0b013e328351fa4d.","journal-title":"Melanoma Res"},{"key":"2694_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","volume":"5","author":"RA Scolyer","year":"2011","unstructured":"Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol. 2011;5:124\u201336. https:\/\/doi.org\/10.1016\/j.molonc.2011.03.002.","journal-title":"Mol Oncol"},{"key":"2694_CR7","doi-asserted-by":"publisher","first-page":"106132","DOI":"10.18632\/oncotarget.22190","volume":"8","author":"A Passarelli","year":"2017","unstructured":"Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8:106132\u201342. https:\/\/doi.org\/10.18632\/oncotarget.22190.","journal-title":"Oncotarget"},{"key":"2694_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/82_2017_61","volume-title":"Emerging concepts targeting immune checkpoints in cancer and autoimmunity","author":"S Chikuma","year":"2017","unstructured":"Chikuma S. Emerging concepts targeting immune checkpoints in cancer and autoimmunity. In: Yoshimura A, editor. Emerging concepts targeting immune checkpoints in cancer and autoimmunity. Springer International Publishing; 2017. p. 99\u2013126."},{"key":"2694_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume-title":"Regulation of cancer immune checkpoints: Molecular and cellular mechanisms and therapy","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J. Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy. In: Xu J, editor. Regulation of cancer immune checkpoints: Molecular and cellular mechanisms and therapy. Springer Singapore; 2020. p. 7\u201332."},{"key":"2694_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001.","journal-title":"Cancer Cell"},{"key":"2694_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0140-6736(21)01206-x","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(21)01206-x.","journal-title":"Lancet"},{"key":"2694_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cbdd.13677","volume":"95","author":"M Kalim","year":"2020","unstructured":"Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: a dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des. 2020;95:552\u201366. https:\/\/doi.org\/10.1111\/cbdd.13677.","journal-title":"Chem Biol Drug Des"},{"key":"2694_CR13","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, et al. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers. 2023;15:2718.","journal-title":"Cancers"},{"key":"2694_CR14","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-Cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543\u201353. https:\/\/doi.org\/10.1128\/MCB.25.21.9543-9553.2005.","journal-title":"Mol Cell Biol"},{"key":"2694_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425\u201334. https:\/\/doi.org\/10.1038\/s41590-019-0512-0.","journal-title":"Nat Immunol"},{"key":"2694_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","volume":"19","author":"ME Keir","year":"2007","unstructured":"Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19:309\u201314. https:\/\/doi.org\/10.1016\/j.coi.2007.04.012.","journal-title":"Curr Opin Immunol"},{"key":"2694_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","volume":"229","author":"JL Riley","year":"2009","unstructured":"Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114\u201325. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00767.x.","journal-title":"Immunol Rev"},{"key":"2694_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4049\/jimmunol.1601464","volume":"198","author":"AP Bally","year":"2017","unstructured":"Bally AP, et al. Conserved region C functions to regulate PD-1 expression and subsequent CD8 T cell memory. J Immunol. 2017;198:205\u201317.","journal-title":"J Immunol"},{"key":"2694_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"2694_CR20","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","volume":"194","author":"AP Bally","year":"2015","unstructured":"Bally AP, et al. NF-\u03baB regulates PD-1 expression in macrophages. J Immunol. 2015;194:4545\u201354.","journal-title":"J Immunol"},{"key":"2694_CR21","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008;181:4832\u20139.","journal-title":"J Immunol"},{"key":"2694_CR22","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1302750","volume":"192","author":"JW Austin","year":"2014","unstructured":"Austin JW, Lu P, Majumder P, Ahmed R, Boss JM. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol. 2014;192:4876\u201386.","journal-title":"J Immunol"},{"key":"2694_CR23","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242\u201356.","journal-title":"Cell"},{"key":"2694_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","volume":"35","author":"B Youngblood","year":"2011","unstructured":"Youngblood B, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells. Immunity. 2011;35:400\u201312.","journal-title":"Immunity"},{"key":"2694_CR25","doi-asserted-by":"publisher","first-page":"8934","DOI":"10.1128\/JVI.00798-16","volume":"90","author":"E Ahn","year":"2016","unstructured":"Ahn E, et al. Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 t cell exhaustion. J Virol. 2016;90:8934\u201346.","journal-title":"J Virol"},{"key":"2694_CR26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","volume":"41","author":"MM Staron","year":"2014","unstructured":"Staron MM, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection. Immunity. 2014;41:802\u201314.","journal-title":"Immunity"},{"key":"2694_CR27","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.4049\/jimmunol.1300675","volume":"192","author":"S Nakayamada","year":"2014","unstructured":"Nakayamada S, et al. Type I IFN induces binding of STAT1 to Bcl6: divergent roles of STAT family transcription factors in the t follicular helper cell genetic program. J Immunol. 2014;192:2156\u201366.","journal-title":"J Immunol"},{"key":"2694_CR28","doi-asserted-by":"publisher","first-page":"694145","DOI":"10.3389\/fonc.2021.694145","volume":"11","author":"S Bao","year":"2021","unstructured":"Bao S, Jiang X, Jin S, Tu P, Lu J. TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on t lymphocytes in hepatocellular carcinoma. Front Oncol. 2021;11:694145.","journal-title":"Front Oncol"},{"key":"2694_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/cmi.2014.49","volume":"12","author":"L Hou","year":"2015","unstructured":"Hou L, et al. Type 1 interferon-induced IL-7 maintains CD8+ t-cell responses and homeostasis by suppressing PD-1 expression in viral hepatitis. Cell Mol Immunol. 2015;12:213\u201322.","journal-title":"Cell Mol Immunol"},{"key":"2694_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang AC, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25:454\u201361.","journal-title":"Nat Med"},{"key":"2694_CR31","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"2694_CR32","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363\u201376.","journal-title":"N Engl J Med"},{"key":"2694_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355\u201363.","journal-title":"Cancer Discov"},{"key":"2694_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665\u201374.","journal-title":"Cancer Res"},{"key":"2694_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u201331.","journal-title":"Science"},{"key":"2694_CR36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","volume":"19","author":"X Jiang","year":"2013","unstructured":"Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19:598\u2013609.","journal-title":"Clin Cancer Res"},{"key":"2694_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, et al. Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136.","journal-title":"Nature"},{"key":"2694_CR38","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7\u2013H1). Proc Natl Acad Sci. 2008;105:20852\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"2694_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","volume":"25","author":"C Xu","year":"2014","unstructured":"Xu C, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25:590\u2013604.","journal-title":"Cancer Cell"},{"key":"2694_CR40","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/jci80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384\u201391. https:\/\/doi.org\/10.1172\/jci80011.","journal-title":"J Clin Invest"},{"key":"2694_CR41","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"key":"2694_CR42","doi-asserted-by":"publisher","first-page":"43267","DOI":"10.18632\/oncotarget.6530","volume":"6","author":"G Carbotti","year":"2015","unstructured":"Carbotti G, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267\u201380. https:\/\/doi.org\/10.18632\/oncotarget.6530.","journal-title":"Oncotarget"},{"key":"2694_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","volume":"10","author":"M Lienlaf","year":"2016","unstructured":"Lienlaf M, et al. Essential role of HDAC6 in the regulation of PD-L1 in\u00a0melanoma. Mol Oncol. 2016;10:735\u201350. https:\/\/doi.org\/10.1016\/j.molonc.2015.12.012.","journal-title":"Mol Oncol"},{"key":"2694_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3892\/or.2012.1822","volume":"28","author":"XY Ni","year":"2012","unstructured":"Ni XY, et al. TGF-\u03b2 of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep. 2012;28:615\u201321. https:\/\/doi.org\/10.3892\/or.2012.1822.","journal-title":"Oncol Rep"},{"key":"2694_CR45","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.4049\/jimmunol.0900974","volume":"183","author":"V Pulko","year":"2009","unstructured":"Pulko V, et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol. 2009;183:3634\u201341. https:\/\/doi.org\/10.4049\/jimmunol.0900974.","journal-title":"J Immunol"},{"key":"2694_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1479-5876-12-151","volume":"12","author":"D Quandt","year":"2014","unstructured":"Quandt D, Jasinski-Bergner S, M\u00fcller U, Schulze B, Seliger B. Synergistic effects of IL-4 and TNF\u03b1 on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med. 2014;12:151. https:\/\/doi.org\/10.1186\/1479-5876-12-151.","journal-title":"J Transl Med"},{"key":"2694_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122540","author":"Q Wang","year":"2017","unstructured":"Wang Q, et al. The roles of micrornas in regulating the expression of PD-1\/PD-L1 immune checkpoint. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18122540.","journal-title":"Int J Mol Sci"},{"key":"2694_CR48","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","volume":"49","author":"N Zhang","year":"2016","unstructured":"Zhang N, et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016;49:1360\u20138. https:\/\/doi.org\/10.3892\/ijo.2016.3632.","journal-title":"Int J Oncol"},{"key":"2694_CR49","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241. https:\/\/doi.org\/10.1038\/ncomms6241.","journal-title":"Nat Commun"},{"key":"2694_CR50","doi-asserted-by":"publisher","unstructured":"Cortez MA, et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108. https:\/\/doi.org\/10.1093\/jnci\/djv303.","DOI":"10.1093\/jnci\/djv303"},{"key":"2694_CR51","doi-asserted-by":"publisher","first-page":"e0168822","DOI":"10.1371\/journal.pone.0168822","volume":"12","author":"G Xie","year":"2017","unstructured":"Xie G, et al. Helicobacter pylori promote B7-H1 expression by suppressing miR-152 and miR-200b in gastric cancer cells. PLoS ONE. 2017;12:e0168822. https:\/\/doi.org\/10.1371\/journal.pone.0168822.","journal-title":"PLoS ONE"},{"key":"2694_CR52","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1038\/ncomms11406","volume":"7","author":"S Xu","year":"2016","unstructured":"Xu S, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016;7:11406. https:\/\/doi.org\/10.1038\/ncomms11406.","journal-title":"Nat Commun"},{"key":"2694_CR53","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/or.2017.5972","volume":"38","author":"M Nowacka-Zawisza","year":"2017","unstructured":"Nowacka-Zawisza M, Wi\u015bnik E. DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review). Oncol Rep. 2017;38:2587\u201396. https:\/\/doi.org\/10.3892\/or.2017.5972.","journal-title":"Oncol Rep"},{"key":"2694_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/ijo.2022.5424","volume":"61","author":"X Ma","year":"2022","unstructured":"Ma X, et al. Epigenetic modifications: critical participants of the PD-L1 regulatory mechanism in solid tumors (Review). Int J Oncol. 2022;61:134. https:\/\/doi.org\/10.3892\/ijo.2022.5424.","journal-title":"Int J Oncol"},{"key":"2694_CR55","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.Cir-15-0077-t","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3:1375\u201385. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0077-t.","journal-title":"Cancer Immunol Res"},{"key":"2694_CR56","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg SJ, et al. BET-Bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18:2162\u201374. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.011.","journal-title":"Cell Rep"},{"key":"2694_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14:10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5.","journal-title":"J Hematol Oncol"},{"key":"2694_CR58","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.sbi.2022.102345","volume":"73","author":"EC Carroll","year":"2022","unstructured":"Carroll EC, Marqusee S. Site-specific ubiquitination: deconstructing the degradation tag. Curr Opin Struct Biol. 2022;73:102345. https:\/\/doi.org\/10.1016\/j.sbi.2022.102345.","journal-title":"Curr Opin Struct Biol"},{"key":"2694_CR59","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955. https:\/\/doi.org\/10.1038\/s41419-020-03140-2.","journal-title":"Cell Death Dis"},{"key":"2694_CR60","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.3390\/ijms25052939","volume":"25","author":"S-B Kim","year":"2024","unstructured":"Kim S-B, Hwang S, Cha J-Y, Lee H-J. Programmed Death Ligand 1 regulatory crosstalk with ubiquitination and deubiquitination: Implications in cancer immunotherapy. Int J Mol Sci. 2024;25:2939.","journal-title":"Int J Mol Sci"},{"key":"2694_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007415","author":"Z Sun","year":"2023","unstructured":"Sun Z, et al. Hsa-LINC02418\/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007415.","journal-title":"J Immunother Cancer"},{"key":"2694_CR62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41419-024-06563-3","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, et al. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death Dis. 2024;15:175. https:\/\/doi.org\/10.1038\/s41419-024-06563-3.","journal-title":"Cell Death Dis"},{"key":"2694_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91\u20135. https:\/\/doi.org\/10.1038\/nature25015.","journal-title":"Nature"},{"key":"2694_CR64","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1200\/JCO.2021.39.15_suppl.9502","volume":"39","author":"RN Amaria","year":"2021","unstructured":"Amaria RN, et al. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J Clin Oncol. 2021;39:9502\u20139502. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9502.","journal-title":"J Clin Oncol"},{"key":"2694_CR65","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41467-022-35469-x","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, et al. PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat Commun. 2022;13:7677. https:\/\/doi.org\/10.1038\/s41467-022-35469-x.","journal-title":"Nat Commun"},{"key":"2694_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cac2.12460","volume":"43","author":"J Li","year":"2023","unstructured":"Li J, et al. USP51\/PD-L1\/ITGB1-deployed juxtacrine interaction plays a cell-intrinsic role in promoting chemoresistant phenotypes in non-small cell lung cancer. Cancer Commun (Lond). 2023;43:765\u201387. https:\/\/doi.org\/10.1002\/cac2.12460.","journal-title":"Cancer Commun (Lond)"},{"key":"2694_CR67","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bbamcr.2008.07.014","volume":"1793","author":"E-L Eskelinen","year":"2009","unstructured":"Eskelinen E-L, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009;1793:664\u201373. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.07.014.","journal-title":"Biochim Biophys Acta"},{"key":"2694_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell\u2013mediated cytotoxicity. Nat Chem Biol. 2019;15:42\u201350. https:\/\/doi.org\/10.1038\/s41589-018-0161-x.","journal-title":"Nat Chem Biol"},{"key":"2694_CR69","doi-asserted-by":"publisher","first-page":"2001596","DOI":"10.1002\/advs.202001596","volume":"8","author":"H Li","year":"2021","unstructured":"Li H, et al. The beneficial role of Sunitinib in tumor immune surveillance by regulating tumor PD-L1. Adv Sci (Weinh). 2021;8:2001596. https:\/\/doi.org\/10.1002\/advs.202001596.","journal-title":"Adv Sci (Weinh)"},{"key":"2694_CR70","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","volume":"57","author":"L Liang","year":"2025","unstructured":"Liang L, et al. Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat Genet. 2025;57:680\u201393. https:\/\/doi.org\/10.1038\/s41588-025-02077-6.","journal-title":"Nat Genet"},{"key":"2694_CR71","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"2694_CR72","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"2694_CR73","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"2694_CR74","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"key":"2694_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/intimm\/13.4.529","volume":"13","author":"J-H Huang","year":"2001","unstructured":"Huang J-H, Tykocinski ML. CTLA-4\u2013Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int Immunol. 2001;13:529\u201339. https:\/\/doi.org\/10.1093\/intimm\/13.4.529.","journal-title":"Int Immunol"},{"key":"2694_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","volume":"19","author":"B Salomon","year":"2001","unstructured":"Salomon B, Bluestone JA. Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225\u201352. https:\/\/doi.org\/10.1146\/annurev.immunol.19.1.225.","journal-title":"Annu Rev Immunol"},{"key":"2694_CR77","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.4049\/jimmunol.156.11.4154","volume":"156","author":"D Perkins","year":"1996","unstructured":"Perkins D, et al. Regulation of CTLA-4 expression during t cell activation. J Immunol. 1996;156:4154\u20139.","journal-title":"J Immunol"},{"key":"2694_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2016.03.007","volume":"178","author":"V Klepsch","year":"2016","unstructured":"Klepsch V, Hermann-Kleiter N, Baier G. Beyond CTLA-4 and PD-1: orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunol Lett. 2016;178:31\u20136. https:\/\/doi.org\/10.1016\/j.imlet.2016.03.007.","journal-title":"Immunol Lett"},{"key":"2694_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271\u20135.","journal-title":"Science"},{"key":"2694_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)04001-7","volume":"104","author":"IM Djuretic","year":"2009","unstructured":"Djuretic IM, Cruz-Guilloty F, Rao A. Regulation of gene expression in peripheral T cells by Runx transcription factors. Adv Immunol. 2009;104:1\u201323.","journal-title":"Adv Immunol"},{"key":"2694_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110124","author":"J Li","year":"2021","unstructured":"Li J, et al. Control of Foxp3 induction and maintenance by sequential histone acetylation and DNA demethylation. Cell Rep. 2021. https:\/\/doi.org\/10.1016\/j.celrep.2021.110124.","journal-title":"Cell Rep"},{"key":"2694_CR82","doi-asserted-by":"publisher","first-page":"144888","DOI":"10.1016\/j.gene.2020.144888","volume":"754","author":"N Skafi","year":"2020","unstructured":"Skafi N, Fayyad-Kazan M, Badran B. Immunomodulatory role for microRNAs: regulation of PD-1\/PD-L1 and CTLA-4 immune checkpoints expression. Gene. 2020;754:144888.","journal-title":"Gene"},{"key":"2694_CR83","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.diabres.2018.05.044","volume":"142","author":"M Zurawek","year":"2018","unstructured":"Zurawek M, et al. miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract. 2018;142:146\u201353. https:\/\/doi.org\/10.1016\/j.diabres.2018.05.044.","journal-title":"Diabetes Res Clin Pract"},{"key":"2694_CR84","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.immuni.2010.09.006","volume":"33","author":"T Yokosuka","year":"2010","unstructured":"Yokosuka T, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity. 2010;33:326\u201339.","journal-title":"Immunity"},{"key":"2694_CR85","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.4049\/jimmunol.163.4.1868","volume":"163","author":"H Schneider","year":"1999","unstructured":"Schneider H, et al. Cytolytic T lymphocyte-associated antigen-4 and the TCR\u03b6\/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol. 1999;163:1868\u201379.","journal-title":"J Immunol"},{"key":"2694_CR86","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with Ipilimumab in patients with metastatic Melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"2694_CR87","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced Melanoma. N Engl J Med. 2019;381:1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"key":"2694_CR88","doi-asserted-by":"crossref","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2020-001014"},{"key":"2694_CR89","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"B Huard","year":"1997","unstructured":"Huard B, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997;94:5744\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2694_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20806","author":"K Chen","year":"2023","unstructured":"Chen K, et al. Fgl1-lag3 axis impairs IL-10-producing regulatory t cells associated with Systemic Lupus Erythematosus disease activity. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20806.","journal-title":"Heliyon"},{"key":"2694_CR91","doi-asserted-by":"publisher","first-page":"615317","DOI":"10.3389\/fimmu.2020.615317","volume":"11","author":"CG Graydon","year":"2021","unstructured":"Graydon CG, Mohideen S, Fowke KR. LAG3\u2019s enigmatic mechanism of action. Front Immunol. 2021;11:615317.","journal-title":"Front Immunol"},{"key":"2694_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s002510050411","volume":"48","author":"D Bruniquel","year":"1998","unstructured":"Bruniquel D, Borie N, Hannier S, Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics. 1998;48:116\u201324.","journal-title":"Immunogenetics"},{"key":"2694_CR93","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.4049\/jimmunol.173.11.6806","volume":"173","author":"N Li","year":"2004","unstructured":"Li N, Workman CJ, Martin SM, Vignali DA. Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol. 2004;173:6806\u201312.","journal-title":"J Immunol"},{"key":"2694_CR94","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","volume":"39","author":"EJ Lipson","year":"2021","unstructured":"Lipson EJ, et al. Relatlimab (RELA) plus Nivolumab (NIVO) versus NIVO in first-line advanced Melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39:9503\u20139503. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9503.","journal-title":"J Clin Oncol"},{"key":"2694_CR95","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2174\/0929867328666210806120904","volume":"29","author":"X Lu","year":"2022","unstructured":"Lu X. Structure and functions of T-cell immunoglobulin-domain and mucin-domain protein 3 in cancer. Curr Med Chem. 2022;29:1851\u201365.","journal-title":"Curr Med Chem"},{"key":"2694_CR96","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim\u20103 and its role in regulating anti\u2010tumor immunity. Immunol Rev. 2017;276:97\u2013111.","journal-title":"Immunol Rev"},{"key":"2694_CR97","unstructured":"Su EW. TIM-3 and Galectin-9 Regulation of effector T cell activation and function. University of Pittsburgh; 2011."},{"key":"2694_CR98","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez GJ, et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity. 2015;42:265\u201378.","journal-title":"Immunity"},{"key":"2694_CR99","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/eji.200939842","volume":"40","author":"AC Anderson","year":"2010","unstructured":"Anderson AC, et al. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol. 2010;40:859\u201366.","journal-title":"Eur J Immunol"},{"key":"2694_CR100","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1038\/ncomms7072","volume":"6","author":"C Zhu","year":"2015","unstructured":"Zhu C, et al. An IL-27\/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun. 2015;6:6072. https:\/\/doi.org\/10.1038\/ncomms7072.","journal-title":"Nat Commun"},{"key":"2694_CR101","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/eji.201344392","volume":"44","author":"AS Gautron","year":"2014","unstructured":"Gautron AS, Dominguez\u2010Villar M, de Marcken M, Hafler DA. Enhanced suppressor function of TIM\u20103+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703\u201311.","journal-title":"Eur J Immunol"},{"key":"2694_CR102","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.coi.2011.12.005","volume":"24","author":"AC Anderson","year":"2012","unstructured":"Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24:213\u20136.","journal-title":"Curr Opin Immunol"},{"key":"2694_CR103","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/onc.2010.292","volume":"29","author":"J Stagg","year":"2010","unstructured":"Stagg J, Smyth M. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346\u201358.","journal-title":"Oncogene"},{"key":"2694_CR104","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11302-005-5302-5","volume":"2","author":"SP Colgan","year":"2006","unstructured":"Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5\u2019-nucleotidase (CD73). Purinergic Signal. 2006;2:351\u201360.","journal-title":"Purinergic Signal"},{"key":"2694_CR105","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hask\u00f3 G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355\u201367.","journal-title":"Trends Mol Med"},{"key":"2694_CR106","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fimmu.2018.00813","volume":"9","author":"T Korda\u00df","year":"2018","unstructured":"Korda\u00df T, Osen W, Eichm\u00fcller SB. Controlling the immune suppressor: transcription factors and micrornas regulating CD73\/NT5E. Front Immunol. 2018;9:813.","journal-title":"Front Immunol"},{"key":"2694_CR107","doi-asserted-by":"publisher","first-page":"11759","DOI":"10.3390\/ijms241411759","volume":"24","author":"N Bach","year":"2023","unstructured":"Bach N, Winzer R, Tolosa E, Fiedler W, Brauneck F. The clinical significance of CD73 in cancer. Int J Mol Sci. 2023;24:11759.","journal-title":"Int J Mol Sci"},{"key":"2694_CR108","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.4049\/jimmunol.172.3.1646","volume":"172","author":"J Niemel\u00e4","year":"2004","unstructured":"Niemel\u00e4 J, et al. IFN-\u03b1 induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5\u2032-nucleotidase) up-regulation. J Immunol. 2004;172:1646\u201353.","journal-title":"J Immunol"},{"key":"2694_CR109","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/eji.200737793","volume":"37","author":"J Kiss","year":"2007","unstructured":"Kiss J, et al. IFN-\u03b2 protects from vascular leakage via up-regulation of CD73. Eur J Immunol. 2007;37:3334\u20138.","journal-title":"Eur J Immunol"},{"key":"2694_CR110","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/eji.201141512","volume":"41","author":"FS Regateiro","year":"2011","unstructured":"Regateiro FS, et al. Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-\u03b2. Eur J Immunol. 2011;41:2955\u201365.","journal-title":"Eur J Immunol"},{"key":"2694_CR111","doi-asserted-by":"publisher","first-page":"e1320011","DOI":"10.1080\/2162402X.2017.1320011","volume":"6","author":"J Li","year":"2017","unstructured":"Li J, et al. CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-\u03b2-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017;6:e1320011.","journal-title":"Oncoimmunology"},{"key":"2694_CR112","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/1078-0432.CCR-0811-03","volume":"10","author":"J Spychala","year":"2004","unstructured":"Spychala J, et al. Role of estrogen receptor in the regulation of ecto-5\u2032-nucleotidase and adenosine in breast cancer. Clin Cancer Res. 2004;10:708\u201317.","journal-title":"Clin Cancer Res"},{"key":"2694_CR113","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/bjc.2012.95","volume":"106","author":"H Wang","year":"2012","unstructured":"Wang H, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012;106:1446\u201352.","journal-title":"Br J Cancer"},{"key":"2694_CR114","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1091\/mbc.e14-06-1167","volume":"25","author":"NT Snider","year":"2014","unstructured":"Snider NT, et al. Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5\u2032-nucleotidase (CD73). Mol Biol Cell. 2014;25:4024\u201333.","journal-title":"Mol Biol Cell"},{"key":"2694_CR115","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.Ccr-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19:5626\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0545.","journal-title":"Clin Cancer Res"},{"key":"2694_CR116","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/jco.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, et al. COAST: an open-label, phase II, multidrug platform study of Durvalumab alone or in combination with Oleclumab or Monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:3383\u201393. https:\/\/doi.org\/10.1200\/jco.22.00227.","journal-title":"J Clin Oncol"},{"key":"2694_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04283-z","author":"ZA Wainberg","year":"2026","unstructured":"Wainberg ZA, et al. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04283-z.","journal-title":"Nat Med"},{"key":"2694_CR118","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(89)90690-9","volume":"56","author":"CL Mendelsohn","year":"1989","unstructured":"Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for Poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855\u201365. https:\/\/doi.org\/10.1016\/0092-8674(89)90690-9.","journal-title":"Cell"},{"key":"2694_CR119","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrm2457","volume":"9","author":"Y Takai","year":"2008","unstructured":"Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9:603\u201315.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2694_CR120","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.str.2018.10.023","volume":"27","author":"FA Deuss","year":"2019","unstructured":"Deuss FA, Watson GM, Fu Z, Rossjohn J, Berry R. Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155. Structure. 2019;27:219-228. e213.","journal-title":"Structure"},{"key":"2694_CR121","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/1566524021666210910112906","volume":"22","author":"SS Nandi","year":"2022","unstructured":"Nandi SS, et al. CD155: a key receptor playing diversified roles. Curr Mol Med. 2022;22:594\u2013607.","journal-title":"Curr Mol Med"},{"key":"2694_CR122","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.bbrc.2004.05.111","volume":"319","author":"T Oda","year":"2004","unstructured":"Oda T, Ohka S, Nomoto A. Ligand stimulation of CD155\u03b1 inhibits cell adhesion and enhances cell migration in fibroblasts. Biochem Biophys Res Commun. 2004;319:1253\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"2694_CR123","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/j.1460-2075.1990.tb07520.x","volume":"9","author":"S Koike","year":"1990","unstructured":"Koike S, et al. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J. 1990;9:3217\u201324.","journal-title":"EMBO J"},{"key":"2694_CR124","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0006-291X(03)01560-2","volume":"309","author":"B Baury","year":"2003","unstructured":"Baury B, et al. Identification of secreted CD155 isoforms. Biochem Biophys Res Commun. 2003;309:175\u201382.","journal-title":"Biochem Biophys Res Commun"},{"key":"2694_CR125","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/j.1460-2075.1990.tb07520.x","volume":"9","author":"S Koike","year":"1990","unstructured":"Koike S, et al. The Poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J. 1990;9:3217\u201324. https:\/\/doi.org\/10.1002\/j.1460-2075.1990.tb07520.x.","journal-title":"EMBO J"},{"key":"2694_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02068-5","volume":"40","author":"B Wu","year":"2021","unstructured":"Wu B, et al. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res. 2021;40:1\u201316.","journal-title":"J Exp Clin Cancer Res"},{"key":"2694_CR127","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT\/CD226 axis regulates human T cell function. J Immunol. 2012;188:3869\u201375.","journal-title":"J Immunol"},{"key":"2694_CR128","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26:923\u201337.","journal-title":"Cancer Cell"},{"key":"2694_CR129","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895.","journal-title":"Front Immunol"},{"key":"2694_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","author":"J-M Chauvin","year":"2020","unstructured":"Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000957.","journal-title":"J Immunother Cancer"},{"key":"2694_CR131","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/BMBRep.2021.54.1.229","volume":"54","author":"H-s Jin","year":"2021","unstructured":"Jin H-s, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54:2.","journal-title":"BMB Rep"},{"key":"2694_CR132","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3799","volume":"15","author":"L Martinet","year":"2015","unstructured":"Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15:243\u201354.","journal-title":"Nat Rev Immunol"},{"key":"2694_CR133","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imcb.12205","volume":"97","author":"A Lepletier","year":"2019","unstructured":"Lepletier A, et al. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. Immunol Cell Biol. 2019;97:152\u201364.","journal-title":"Immunol Cell Biol"},{"key":"2694_CR134","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2013.12.011","volume":"40","author":"T Nabekura","year":"2014","unstructured":"Nabekura T, et al. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity. 2014;40:225\u201334.","journal-title":"Immunity"},{"key":"2694_CR135","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.immuni.2020.09.010","volume":"53","author":"M Braun","year":"2020","unstructured":"Braun M, et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+T cells. Immunity. 2020;53:805-823.e815. https:\/\/doi.org\/10.1016\/j.immuni.2020.09.010.","journal-title":"Immunity"},{"key":"2694_CR136","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12518","volume":"276","author":"WC Dougall","year":"2017","unstructured":"Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112\u201320.","journal-title":"Immunol Rev"},{"key":"2694_CR137","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/eji.201948405","volume":"50","author":"EY Chiang","year":"2020","unstructured":"Chiang EY, et al. CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses. Eur J Immunol. 2020;50:891\u2013902.","journal-title":"Eur J Immunol"},{"key":"2694_CR138","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ. In Seminars in cancer biology. 189\u2013196 (Elsevier)."},{"key":"2694_CR139","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/s41423-020-00538-y","volume":"18","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma. Cell Mol Immunol. 2021;18:1575\u20137.","journal-title":"Cell Mol Immunol"},{"key":"2694_CR140","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007340","author":"SP Patel","year":"2024","unstructured":"Patel SP, et al. Phase 1\/2 study of Monalizumab plus Durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-007340.","journal-title":"J Immunother Cancer"},{"key":"2694_CR141","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, et al. Tiragolumab plus Atezolizumab versus placebo plus Atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23:781\u201392. https:\/\/doi.org\/10.1016\/s1470-2045(22)00226-1.","journal-title":"Lancet Oncol"},{"key":"2694_CR142","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-981-32-9717-3_2","volume-title":"Co-signal molecules in T Cell activation: immune regulation in health and disease","author":"S Nagai","year":"2019","unstructured":"Nagai S, Azuma M. The CD28\u2013B7 family of co-signaling molecules. In: Co-signal molecules in T Cell activation: immune regulation in health and disease. 2019. p. 25\u201351."},{"key":"2694_CR143","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1074-7613(00)80479-3","volume":"4","author":"CE Rudd","year":"1996","unstructured":"Rudd CE. Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity. 1996;4:527\u201334.","journal-title":"Immunity"},{"key":"2694_CR144","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-042617-053429","volume":"36","author":"A Alcover","year":"2018","unstructured":"Alcover A, Alarc\u00f3n B, Di Bartolo V. Cell biology of T cell receptor expression and regulation. Annu Rev Immunol. 2018;36:103\u201325.","journal-title":"Annu Rev Immunol"},{"key":"2694_CR145","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/0952-7915(94)90120-1","volume":"6","author":"JP Allison","year":"1994","unstructured":"Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994;6:414\u20139.","journal-title":"Curr Opin Immunol"},{"key":"2694_CR146","doi-asserted-by":"crossref","unstructured":"Beyersdorf N, Kerkau T, H\u00fcnig T. CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther. 2015;111\u201322.","DOI":"10.2147\/ITT.S61647"},{"key":"2694_CR147","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","volume":"295","author":"H Huang","year":"2020","unstructured":"Huang H, Long L, Zhou P, Chapman NM, Chi H. mTOR signaling at the crossroads of environmental signals and T-cell fate decisions. Immunol Rev. 2020;295:15\u201338.","journal-title":"Immunol Rev"},{"key":"2694_CR148","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1600-065X.2009.00773.x","volume":"229","author":"JR Podojil","year":"2009","unstructured":"Podojil JR, Miller SD. Molecular mechanisms of T\u2010cell receptor and costimulatory molecule ligation\/blockade in autoimmune disease therapy. Immunol Rev. 2009;229:337\u201355.","journal-title":"Immunol Rev"},{"key":"2694_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01719","volume":"10","author":"A Xia","year":"2019","unstructured":"Xia A, Zhang Y, Xu J, Yin T, Lu X-J. T cell dysfunction in cancer immunity and immunotherapy. Front Immunol. 2019;10:1719.","journal-title":"Front Immunol"},{"key":"2694_CR150","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/bmj.38797.635012.47","volume":"332","author":"M Goodyear","year":"2006","unstructured":"Goodyear M. Learning from the TGN1412 trial. BMJ. 2006;332:677\u20138. https:\/\/doi.org\/10.1136\/bmj.38797.635012.47.","journal-title":"BMJ"},{"key":"2694_CR151","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22:3425\u201331.","journal-title":"Clin Cancer Res"},{"key":"2694_CR152","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, et al. Immune checkpoint of B7\u2013H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15:153.","journal-title":"J Hematol Oncol"},{"key":"2694_CR153","doi-asserted-by":"publisher","first-page":"108153","DOI":"10.1016\/j.intimp.2021.108153","volume":"101","author":"R Feng","year":"2021","unstructured":"Feng R, Chen Y, Liu Y, Zhou Q, Zhang W. The role of B7\u2013H3 in tumors and its potential in clinical application. Int Immunopharmacol. 2021;101:108153.","journal-title":"Int Immunopharmacol"},{"key":"2694_CR154","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724.","journal-title":"Sci Transl Med"},{"key":"2694_CR155","doi-asserted-by":"publisher","first-page":"27528","DOI":"10.1038\/srep27528","volume":"6","author":"C Xie","year":"2016","unstructured":"Xie C, et al. Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4\/NF-\u03baB pathway. Sci Rep. 2016;6:27528.","journal-title":"Sci Rep"},{"key":"2694_CR156","doi-asserted-by":"publisher","first-page":"816","DOI":"10.7150\/jca.17759","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, et al. B7\u2013H3 promotes the migration and invasion of human bladder cancer cells via the PI3K\/Akt\/STAT3 signaling pathway. J Cancer. 2017;8:816.","journal-title":"J Cancer"},{"key":"2694_CR157","doi-asserted-by":"publisher","first-page":"2805576","DOI":"10.1155\/2021\/2805576","volume":"2021","author":"T-T Yu","year":"2021","unstructured":"Yu T-T, et al. ELK1 promotes epithelial-mesenchymal transition and the progression of lung adenocarcinoma by upregulating B7\u2013H3. Oxid Med Cell Longev. 2021;2021:2805576.","journal-title":"Oxid Med Cell Longev"},{"key":"2694_CR158","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.febslet.2015.06.037","volume":"589","author":"P Zhang","year":"2015","unstructured":"Zhang P, et al. ILT4 drives B7\u2013H3 expression via PI3K\/AKT\/mTOR signalling and ILT4\/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett. 2015;589:2248\u201356.","journal-title":"FEBS Lett"},{"key":"2694_CR159","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bbrc.2013.07.095","volume":"438","author":"J Zhao","year":"2013","unstructured":"Zhao J, et al. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7\u2013H3. Biochem Biophys Res Commun. 2013;438:439\u201344.","journal-title":"Biochem Biophys Res Commun"},{"key":"2694_CR160","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.biocel.2019.01.011","volume":"108","author":"J Zhao","year":"2019","unstructured":"Zhao J, et al. B7\u2013H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2019;108:84\u201391.","journal-title":"Int J Biochem Cell Biol"},{"key":"2694_CR161","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12013-021-00975-0","volume":"79","author":"X Hu","year":"2021","unstructured":"Hu X, Xu M, Hu Y, Li N, Zhou L. B7\u2013H3, negatively regulated by miR-128, promotes colorectal cancer cell proliferation and migration. Cell Biochem Biophys. 2021;79:397\u2013405.","journal-title":"Cell Biochem Biophys"},{"key":"2694_CR162","doi-asserted-by":"publisher","first-page":"153303382094224","DOI":"10.1177\/1533033820942245","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Feng K-X, Li H, Wang L, Xia H. MicroRNA-199a inhibits cell proliferation, migration, and invasion and activates AKT\/mTOR signaling pathway by targeting B7-H3 in cervical cancer. Technol Cancer Res Treat. 2020;19:1533033820942245.","journal-title":"Technol Cancer Res Treat"},{"key":"2694_CR163","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","volume":"69","author":"H Xu","year":"2009","unstructured":"Xu H, Cheung IY, Guo H-F, Cheung N-KV. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7\u2013H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69:6275\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4517.","journal-title":"Cancer Res"},{"key":"2694_CR164","doi-asserted-by":"publisher","first-page":"14939","DOI":"10.1007\/s13277-016-5386-2","volume":"37","author":"L Wang","year":"2016","unstructured":"Wang L, et al. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. Tumor Biol. 2016;37:14939\u201347. https:\/\/doi.org\/10.1007\/s13277-016-5386-2.","journal-title":"Tumor Biol"},{"key":"2694_CR165","doi-asserted-by":"publisher","first-page":"670141","DOI":"10.3389\/fmed.2021.670141","volume":"8","author":"Z Qiu","year":"2021","unstructured":"Qiu Z, Jiang H, Ju K, Liu X. A novel RNA-binding protein signature to predict clinical outcomes and guide clinical therapy in gastric cancer. Front Med. 2021;8:670141.","journal-title":"Front Med"},{"key":"2694_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-020-00233-w","volume":"25","author":"R Li","year":"2020","unstructured":"Li R, et al. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cell Mol Biol Lett. 2020;25:1\u201321.","journal-title":"Cell Mol Biol Lett"},{"key":"2694_CR167","doi-asserted-by":"publisher","first-page":"654684","DOI":"10.3389\/fonc.2021.654684","volume":"11","author":"S Liu","year":"2021","unstructured":"Liu S, et al. The role of CD276 in cancers. Front Oncol. 2021;11:654684.","journal-title":"Front Oncol"},{"key":"2694_CR168","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.3892\/ol.2019.10057","volume":"17","author":"K Iida","year":"2019","unstructured":"Iida K, et al. Prognostic impact of tumor-infiltrating CD276\/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. Oncol Lett. 2019;17:4004\u201310. https:\/\/doi.org\/10.3892\/ol.2019.10057.","journal-title":"Oncol Lett"},{"key":"2694_CR169","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/cells10051020","volume":"10","author":"S Grote","year":"2021","unstructured":"Grote S, et al. In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment. Cells. 2021;10:1020.","journal-title":"Cells"},{"key":"2694_CR170","doi-asserted-by":"crossref","unstructured":"W U, et al. A Phase I, open-label, dose escalation study of MGA271 in combination with. J Immunother Cancer. 2015;3:176.","DOI":"10.1186\/2051-1426-3-S2-P176"},{"key":"2694_CR171","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(15)00083-2.","journal-title":"Lancet Oncol"},{"key":"2694_CR172","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ejca.2021.08.013","volume":"157","author":"O Hamid","year":"2021","unstructured":"Hamid O, et al. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. 2021;157:391\u2013402. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.013.","journal-title":"Eur J Cancer"},{"key":"2694_CR173","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/jco.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, et al. Five-year outcomes with Nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38:3937\u201346. https:\/\/doi.org\/10.1200\/jco.20.00995.","journal-title":"J Clin Oncol"},{"key":"2694_CR174","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, et al. Final, 10-year outcomes with Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2025;392:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"key":"2694_CR175","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/oncolo\/oyae045","volume":"29","author":"B Tang","year":"2024","unstructured":"Tang B, et al. Five-year follow-up of POLARIS-01 Phase II trial: toripalimab as salvage monotherapy in Chinese patients with advanced melanoma. Oncologist. 2024;29:e822\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyae045.","journal-title":"Oncologist"},{"key":"2694_CR176","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoncol.2025.5751","volume":"12","author":"X Sheng","year":"2026","unstructured":"Sheng X, et al. Toripalimab vs dacarbazine as first-line therapy for advanced melanoma of acral subtype: the Phase 3 MELATORCH randomized clinical trial. JAMA Oncol. 2026;12:243\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2025.5751.","journal-title":"JAMA Oncol"},{"key":"2694_CR177","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2022.40.16_suppl.9512","volume":"40","author":"C Cui","year":"2022","unstructured":"Cui C, et al. Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: interim results from a randomized, controlled, phase II trial. J Clin Oncol. 2022;40:9512\u20139512. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9512.","journal-title":"J Clin Oncol"},{"key":"2694_CR178","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2022.40.16_suppl.9508","volume":"40","author":"L Si","year":"2022","unstructured":"Si L, et al. A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM). J Clin Oncol. 2022;40:9508\u20139508. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9508.","journal-title":"J Clin Oncol"},{"key":"2694_CR179","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1200\/JCO.2023.41.16_suppl.9514","volume":"41","author":"L Mao","year":"2023","unstructured":"Mao L, et al. NeoPlus: a phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma. J Clin Oncol. 2023;41:9514\u20139514. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9514.","journal-title":"J Clin Oncol"},{"key":"2694_CR180","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2019.37.8_suppl.15","volume":"37","author":"MH Taylor","year":"2019","unstructured":"Taylor MH, et al. Phase Ib\/II trial of lenvatinib plus pembrolizumab in advanced melanoma. J Clin Oncol. 2019;37:15\u201315. https:\/\/doi.org\/10.1200\/JCO.2019.37.8_suppl.15.","journal-title":"J Clin Oncol"},{"key":"2694_CR181","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","volume":"39","author":"AM Arance","year":"2021","unstructured":"Arance AM, et al. Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004. J Clin Oncol. 2021;39:9504\u20139504. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9504.","journal-title":"J Clin Oncol"},{"key":"2694_CR182","doi-asserted-by":"publisher","first-page":"9553","DOI":"10.1200\/JCO.2025.43.16_suppl.9553","volume":"43","author":"J Guo","year":"2025","unstructured":"Guo J, et al. First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: results from LEAP-003. J Clin Oncol. 2025;43:9553\u20139553. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9553.","journal-title":"J Clin Oncol"},{"key":"2694_CR183","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1200\/JCO.2020.38.15_suppl.10040","volume":"38","author":"L Si","year":"2020","unstructured":"Si L, et al. A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma. J Clin Oncol. 2020;38:10040\u201310040. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.10040.","journal-title":"J Clin Oncol"},{"key":"2694_CR184","doi-asserted-by":"publisher","first-page":"9550","DOI":"10.1200\/JCO.2023.41.16_suppl.9550","volume":"41","author":"L Mao","year":"2023","unstructured":"Mao L, et al. Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma. J Clin Oncol. 2023;41:9550\u20139550. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9550.","journal-title":"J Clin Oncol"},{"key":"2694_CR185","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.1200\/JCO.2023.41.16_suppl.9563","volume":"41","author":"GT Gibney","year":"2023","unstructured":"Gibney GT, et al. Interim analysis of a phase II study of nivolumab\/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma. J Clin Oncol. 2023;41:9563\u20139563. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9563.","journal-title":"J Clin Oncol"},{"key":"2694_CR186","doi-asserted-by":"publisher","first-page":"e21545","DOI":"10.1200\/JCO.2023.41.16_suppl.e21545","volume":"41","author":"C Cui","year":"2023","unstructured":"Cui C, et al. The phase 1 clinical trial of anti\u2013PD-1 (pucotenlimab) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapy of liver metastasis in stage IV melanoma. J Clin Oncol. 2023;41:e21545\u2013e21545. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e21545.","journal-title":"J Clin Oncol"},{"key":"2694_CR187","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1200\/JCO.2022.40.16_suppl.9551","volume":"40","author":"C Cui","year":"2022","unstructured":"Cui C, et al. Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti\u2013PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage \u2163 melanoma with liver metastases. J Clin Oncol. 2022;40:9551\u20139551. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9551.","journal-title":"J Clin Oncol"},{"key":"2694_CR188","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:9568\u20139568. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.9568.","journal-title":"J Clin Oncol"},{"key":"2694_CR189","doi-asserted-by":"publisher","first-page":"TPS9595","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9595","volume":"40","author":"J Lutzky","year":"2022","unstructured":"Lutzky J, et al. Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non\u2013small cell lung cancer (NSCLC). J Clin Oncol. 2022;40:TPS9595\u2013TPS9595. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS9595.","journal-title":"J Clin Oncol"},{"key":"2694_CR190","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1203475420988862","volume":"25","author":"S Khoury","year":"2021","unstructured":"Khoury S, et al. Durability of complete response to intralesional interleukin-2 for in-transit melanoma. J Cutan Med Surg. 2021;25:364\u201370. https:\/\/doi.org\/10.1177\/1203475420988862.","journal-title":"J Cutan Med Surg"},{"key":"2694_CR191","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1245\/s10434-014-4199-z","volume":"22","author":"S Hassan","year":"2015","unstructured":"Hassan S, et al. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease. Ann Surg Oncol. 2015;22:1950\u20138. https:\/\/doi.org\/10.1245\/s10434-014-4199-z.","journal-title":"Ann Surg Oncol"},{"key":"2694_CR192","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030540","author":"D Rafei-Shamsabadi","year":"2022","unstructured":"Rafei-Shamsabadi D, Lehr S, Behrens M, Meiss F. Additive intralesional Interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030540.","journal-title":"Cancers (Basel)"},{"key":"2694_CR193","doi-asserted-by":"publisher","first-page":"e12901","DOI":"10.1111\/dth.12901","volume":"32","author":"EA Langan","year":"2019","unstructured":"Langan EA, et al. Intralesional interleukin-2: a novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma. Dermatol Ther. 2019;32:e12901. https:\/\/doi.org\/10.1111\/dth.12901.","journal-title":"Dermatol Ther"},{"key":"2694_CR194","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.Cd-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas A, et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a Phase Ib, multicenter study. Cancer Discov. 2018;8:1250\u20137. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0280.","journal-title":"Cancer Discov"},{"key":"2694_CR195","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1200\/JCO.2023.41.16_suppl.9551","volume":"41","author":"SK M\u00f8rk","year":"2023","unstructured":"M\u00f8rk SK, et al. Final results: dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma. J Clin Oncol. 2023;41:9551\u20139551. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9551.","journal-title":"J Clin Oncol"},{"key":"2694_CR196","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1200\/JCO.2021.39.15_suppl.2613","volume":"39","author":"ML Gillison","year":"2021","unstructured":"Gillison ML, et al. Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. J Clin Oncol. 2021;39:2613\u20132613. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2613.","journal-title":"J Clin Oncol"},{"key":"2694_CR197","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1200\/JCO.2021.39.15_suppl.2596","volume":"39","author":"JM Wrangle","year":"2021","unstructured":"Wrangle JM, et al. Preliminary data from QUILT 3.055: A Phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI). J Clin Oncol. 2021;39:2596\u20132596. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2596.","journal-title":"J Clin Oncol"},{"key":"2694_CR198","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.Ccr-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort A, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin Cancer Res. 2021;27:1037\u201347. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3449.","journal-title":"Clin Cancer Res"},{"key":"2694_CR199","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2025.43.16_suppl.9510","volume":"43","author":"JM Mehnert","year":"2025","unstructured":"Mehnert JM, et al. A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2025;43:9510\u20139510. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9510.","journal-title":"J Clin Oncol"},{"key":"2694_CR200","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","volume":"5","author":"SR Gameiro","year":"2014","unstructured":"Gameiro SR, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403\u201316. https:\/\/doi.org\/10.18632\/oncotarget.1719.","journal-title":"Oncotarget"},{"key":"2694_CR201","doi-asserted-by":"publisher","first-page":"TPS9607","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9607","volume":"42","author":"D Davar","year":"2024","unstructured":"Davar D, et al. Randomized Phase II trial of pembrolizumab\/lenvatinib (P+L) +\/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed\/refractory (R\/R) cutaneous melanoma (MEL). J Clin Oncol. 2024;42:TPS9607\u2013TPS9607. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS9607.","journal-title":"J Clin Oncol"},{"key":"2694_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162648","author":"I Gorodetska","year":"2025","unstructured":"Gorodetska I, Schulz A, Behre G, Dubrovska A. Confronting melanoma radioresistance: mechanisms and therapeutic strategies. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17162648.","journal-title":"Cancers (Basel)"},{"key":"2694_CR203","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602. https:\/\/doi.org\/10.1126\/science.abf3363.","journal-title":"Science"},{"key":"2694_CR204","doi-asserted-by":"publisher","unstructured":"Pant S, et al. A phase I\/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. J Clin Oncol. 2019;37:TPS2670\u2013TPS2670. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS2670.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2670"},{"key":"2694_CR205","doi-asserted-by":"publisher","unstructured":"Li J, et al. 838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation. J ImmunoTher Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0838.","DOI":"10.1136\/jitc-2022-SITC2022.0838"},{"key":"2694_CR206","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/jco.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, et al. Combination Dabrafenib and Trametinib versus combination Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41:186\u201397. https:\/\/doi.org\/10.1200\/jco.22.01763.","journal-title":"J Clin Oncol"},{"key":"2694_CR207","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.Ccr-20-3305","volume":"27","author":"MD Hellmann","year":"2021","unstructured":"Hellmann MD, et al. Entinostat plus Pembrolizumab in patients with metastatic NSCLC previously treated with Anti-PD-(L)1 therapy. Clin Cancer Res. 2021;27:1019\u201328. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3305.","journal-title":"Clin Cancer Res"},{"key":"2694_CR208","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol. 2022;13:837230. https:\/\/doi.org\/10.3389\/fimmu.2022.837230.","journal-title":"Front Immunol"},{"key":"2694_CR209","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025;10:104536. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536.","journal-title":"ESMO Open"},{"key":"2694_CR210","doi-asserted-by":"publisher","first-page":"002371","DOI":"10.1136\/jitc-2021-002371","volume":"9","author":"BD Curti","year":"2021","unstructured":"Curti BD, et al. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J Immunother Cancer. 2021;9:002371. https:\/\/doi.org\/10.1136\/jitc-2021-002371.","journal-title":"J Immunother Cancer"},{"key":"2694_CR211","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/jco-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, et al. Long-term efficacy and safety of Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study. J Clin Oncol. 2025;43:3565\u201372. https:\/\/doi.org\/10.1200\/jco-25-00765.","journal-title":"J Clin Oncol"},{"key":"2694_CR212","doi-asserted-by":"publisher","unstructured":"Mehta A, et al. Advancements in melanoma treatment: a review of PD-1 Inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte therapy in an evolving landscape of immunotherapy. J Clin Med. 2025;14. https:\/\/doi.org\/10.3390\/jcm14041200.","DOI":"10.3390\/jcm14041200"},{"key":"2694_CR213","doi-asserted-by":"publisher","first-page":"9550","DOI":"10.1200\/JCO.2024.42.16_suppl.9550","volume":"42","author":"R Dummer","year":"2024","unstructured":"Dummer R, et al. Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation\u2013positive melanoma with central nervous system (CNS) metastases (mets): final results and exploratory biomarker analysis from the phase 2 TRICOTEL study. J Clin Oncol. 2024;42:9550\u20139550. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9550.","journal-title":"J Clin Oncol"},{"key":"2694_CR214","doi-asserted-by":"publisher","first-page":"9548","DOI":"10.1200\/JCO.2022.40.16_suppl.9548","volume":"40","author":"D Schadendorf","year":"2022","unstructured":"Schadendorf D, et al. Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: interim analysis of the ImmunoCobiVem study. J Clin Oncol. 2022;40:9548\u20139548. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9548.","journal-title":"J Clin Oncol"},{"key":"2694_CR215","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1200\/JCO.2022.40.16_suppl.9525","volume":"40","author":"L Mao","year":"2022","unstructured":"Mao L, et al. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase 2 study. J Clin Oncol. 2022;40:9525\u20139525. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9525.","journal-title":"J Clin Oncol"},{"key":"2694_CR216","doi-asserted-by":"publisher","first-page":"e21543","DOI":"10.1200\/JCO.2022.40.16_suppl.e21543","volume":"40","author":"L Mao","year":"2022","unstructured":"Mao L, et al. Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma. J Clin Oncol. 2022;40:e21543\u2013e21543. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e21543.","journal-title":"J Clin Oncol"},{"key":"2694_CR217","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/jco.2015.33.15_suppl.3003","volume":"33","author":"A Ribas","year":"2015","unstructured":"Ribas A, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33:3003\u20133003. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3003.","journal-title":"J Clin Oncol"},{"key":"2694_CR218","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1200\/JCO.2021.39.15_suppl.9514","volume":"39","author":"M Kwon","year":"2021","unstructured":"Kwon M, et al. Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy. J Clin Oncol. 2021;39:9514\u20139514. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9514.","journal-title":"J Clin Oncol"},{"key":"2694_CR219","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120:6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y.","journal-title":"Br J Cancer"},{"key":"2694_CR220","doi-asserted-by":"publisher","unstructured":"Robbins Y, et al. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. J Immunother Cancer. 2021;9. https:\/\/doi.org\/10.1136\/jitc-2021-003113.","DOI":"10.1136\/jitc-2021-003113"},{"key":"2694_CR221","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1200\/JCO.2022.40.16_suppl.9561","volume":"40","author":"B Gastman","year":"2022","unstructured":"Gastman B, et al. A phase 1b\/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1\/PD-L1 na\u00efve or relapsed\/refractory (R\/R) high-risk skin cancers: the phase 1b report. J Clin Oncol. 2022;40:9561\u20139561. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9561.","journal-title":"J Clin Oncol"},{"key":"2694_CR222","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/curroncol31010042","volume":"31","author":"R Falcone","year":"2024","unstructured":"Falcone R, et al. Primary mucosal melanoma: clinical experience from a single Italian center. Curr Oncol. 2024;31:588\u201397. https:\/\/doi.org\/10.3390\/curroncol31010042.","journal-title":"Curr Oncol"},{"key":"2694_CR223","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1104621.","journal-title":"N Engl J Med"},{"key":"2694_CR224","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/s1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330. https:\/\/doi.org\/10.1016\/s1470-2045(15)70122-1.","journal-title":"Lancet Oncol"},{"key":"2694_CR225","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1611299.","journal-title":"N Engl J Med"},{"key":"2694_CR226","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/ott.S65802","volume":"9","author":"B Comin-Anduix","year":"2016","unstructured":"Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767\u201376. https:\/\/doi.org\/10.2147\/ott.S65802.","journal-title":"Onco Targets Ther"},{"key":"2694_CR227","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1302369.","journal-title":"N Engl J Med"},{"key":"2694_CR228","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","journal-title":"N Engl J Med"},{"key":"2694_CR229","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"key":"2694_CR230","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/s1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination Nivolumab plus Ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22:1692\u2013704. https:\/\/doi.org\/10.1016\/s1470-2045(21)00545-3.","journal-title":"Lancet Oncol"},{"key":"2694_CR231","doi-asserted-by":"publisher","unstructured":"Tang B, et al. Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-009662.","DOI":"10.1136\/jitc-2024-009662"},{"key":"2694_CR232","doi-asserted-by":"publisher","first-page":"e15111","DOI":"10.1200\/JCO.2020.38.15_suppl.e15111","volume":"38","author":"B Lian","year":"2020","unstructured":"Lian B, et al. IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: an open-label phase Ia\/1b study. J Clin Oncol. 2020;38:e15111\u2013e15111. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e15111.","journal-title":"J Clin Oncol"},{"key":"2694_CR233","doi-asserted-by":"publisher","first-page":"TPS9595","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9595","volume":"41","author":"S Jacob","year":"2023","unstructured":"Jacob S, Daud A. Phase Ib\/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. J Clin Oncol. 2023;41:TPS9595. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9595.","journal-title":"J Clin Oncol"},{"key":"2694_CR234","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/jco.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, et al. Talimogene Laherparepvec in combination with ipilimumab in previously untreated, Unresectable stage IIIB-IV Melanoma. J Clin Oncol. 2016;34:2619\u201326. https:\/\/doi.org\/10.1200\/jco.2016.67.1529.","journal-title":"J Clin Oncol"},{"key":"2694_CR235","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2017.35.15_suppl.3014","volume":"35","author":"BD Curti","year":"2017","unstructured":"Curti BD, et al. Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy. J Clin Oncol. 2017;35:3014\u20133014. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3014.","journal-title":"J Clin Oncol"},{"key":"2694_CR236","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","volume":"35","author":"RHI Andtbacka","year":"2017","unstructured":"Andtbacka RHI, et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and Ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J Clin Oncol. 2017;35:9510\u20139510. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9510.","journal-title":"J Clin Oncol"},{"key":"2694_CR237","doi-asserted-by":"publisher","first-page":"64390","DOI":"10.18632\/oncotarget.10453","volume":"7","author":"A Ray","year":"2016","unstructured":"Ray A, et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016;7:64390\u20139. https:\/\/doi.org\/10.18632\/oncotarget.10453.","journal-title":"Oncotarget."},{"key":"2694_CR238","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","volume":"96","author":"SM Hiniker","year":"2016","unstructured":"Hiniker SM, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2016;96:578\u201388. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.07.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2694_CR239","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2018.36.15_suppl.9520","volume":"36","author":"L Mortier","year":"2018","unstructured":"Mortier L, et al. Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: a multicenter, open label, phase 2 trial. J Clin Oncol. 2018;36:9520\u20139520. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.9520.","journal-title":"J Clin Oncol"},{"key":"2694_CR240","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2022.40.16_suppl.9505","volume":"40","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047. J Clin Oncol. 2022;40:9505\u20139505. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9505.","journal-title":"J Clin Oncol"},{"key":"2694_CR241","doi-asserted-by":"publisher","first-page":"e21511","DOI":"10.1200\/JCO.2022.40.16_suppl.e21511","volume":"40","author":"R-C Nie","year":"2022","unstructured":"Nie R-C, Wang Y, Yuan S-Q, Chen Y, Zhou Z. LAG3-PD1 or CTLA4-PD1 inhibition in advanced melanoma: Indirect cross comparisons of the CheckMate-067 and relativity-047 trials. J Clin Oncol. 2022;40:e21511. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e21511.","journal-title":"J Clin Oncol"},{"key":"2694_CR242","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1200\/JCO.2022.40.16_suppl.9514","volume":"40","author":"L Karapetyan","year":"2022","unstructured":"Karapetyan L, et al. Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy. J Clin Oncol. 2022;40:9514\u20139514. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9514.","journal-title":"J Clin Oncol"},{"key":"2694_CR243","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.1200\/JCO.2023.41.16_suppl.9501","volume":"41","author":"O Hamid","year":"2023","unstructured":"Hamid O, et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. J Clin Oncol. 2023;41:9501\u20139501. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9501.","journal-title":"J Clin Oncol"},{"key":"2694_CR244","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.1200\/JCO.2022.40.16_suppl.9538","volume":"40","author":"X Bai","year":"2022","unstructured":"Bai X, et al. Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase \u2160, open-label, multicenter, dose escalation\/expansion study. J Clin Oncol. 2022;40:9538\u20139538. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9538.","journal-title":"J Clin Oncol"},{"key":"2694_CR245","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2018.36.15_suppl.3012","volume":"36","author":"DS Hong","year":"2018","unstructured":"Hong DS, et al. Phase I\/II study of LAG525 \u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies. J Clin Oncol. 2018;36:3012\u20133012. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.3012.","journal-title":"J Clin Oncol"},{"key":"2694_CR246","doi-asserted-by":"publisher","first-page":"e15099","DOI":"10.1200\/JCO.2018.36.15_suppl.e15099","volume":"36","author":"MA Eastgate","year":"2018","unstructured":"Eastgate MA, et al. Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. J Clin Oncol. 2018;36:e15099\u2013e15099. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e15099.","journal-title":"J Clin Oncol"},{"key":"2694_CR247","doi-asserted-by":"publisher","first-page":"1349081","DOI":"10.3389\/fphar.2023.1349081","volume":"14","author":"J Su","year":"2023","unstructured":"Su J, et al. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Front Pharmacol. 2023;14:1349081. https:\/\/doi.org\/10.3389\/fphar.2023.1349081.","journal-title":"Front Pharmacol"},{"key":"2694_CR248","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, et al. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial. Nat Med. 2025;31:3700\u201312. https:\/\/doi.org\/10.1038\/s41591-025-03967-2.","journal-title":"Nat Med"},{"key":"2694_CR249","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1158\/1538-7445.AM2018-3825","volume":"78","author":"J Waight","year":"2018","unstructured":"Waight J, et al. INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3. Cancer Res. 2018;78:3825.","journal-title":"Cancer Res"},{"key":"2694_CR250","doi-asserted-by":"publisher","unstructured":"Gutierrez ME, et al. First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf144.","DOI":"10.1093\/oncolo\/oyaf144"},{"key":"2694_CR251","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.2023.41.16_suppl.2599","volume":"41","author":"O Hamid","year":"2023","unstructured":"Hamid O, et al. A phase 1\/2 study of retifanlimab (INCMGA00012, Anti\u2013PD-1), INCAGN02385 (Anti\u2013LAG-3), and INCAGN02390 (Anti\u2013TIM-3) combination therapy in patients (Pts) with advanced solid tumors. J Clin Oncol. 2023;41:2599\u20132599. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2599.","journal-title":"J Clin Oncol"},{"key":"2694_CR252","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","volume":"40","author":"GS Falchook","year":"2022","unstructured":"Falchook GS, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). J Clin Oncol. 2022;40:2504. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2504.","journal-title":"J Clin Oncol"},{"key":"2694_CR253","doi-asserted-by":"publisher","first-page":"LBA9504-LBA9504","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9504","volume":"43","author":"M Mooradian","year":"2025","unstructured":"Mooradian M, et al. Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): primary analysis. J Clin Oncol. 2025;43:LBA9504\u2013LBA9504. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA9504.","journal-title":"J Clin Oncol"},{"key":"2694_CR254","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.Ccr-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, et al. Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 Antibody. Advanced Solid Tumors Clin Cancer Res. 2021;27:3620\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4746.","journal-title":"Advanced Solid Tumors Clin Cancer Res"},{"key":"2694_CR255","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102718","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15102718.","journal-title":"Cancers (Basel)"},{"key":"2694_CR256","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"key":"2694_CR257","doi-asserted-by":"publisher","first-page":"CT180","DOI":"10.1158\/1538-7445.Am2018-ct180","volume":"78","author":"LL Siu","year":"2018","unstructured":"Siu LL, et al. Abstract CT180: preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Cancer Res. 2018;78:CT180. https:\/\/doi.org\/10.1158\/1538-7445.Am2018-ct180.","journal-title":"Cancer Res"},{"key":"2694_CR258","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.2021.39.15_suppl.2511","volume":"39","author":"F Robert","year":"2021","unstructured":"Robert F, et al. Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. J Clin Oncol. 2021;39:2511. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2511.","journal-title":"J Clin Oncol"},{"key":"2694_CR259","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2023.41.16_suppl.2570","volume":"41","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, et al. Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b\/2 clinical trial results using CD73 as a potential predictive biomarker. J Clin Oncol. 2023;41:2570\u20132570. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2570.","journal-title":"J Clin Oncol"},{"key":"2694_CR260","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72:2443\u201358. https:\/\/doi.org\/10.1007\/s00262-023-03430-6.","journal-title":"Cancer Immunol Immunother"},{"key":"2694_CR261","doi-asserted-by":"publisher","unstructured":"Mobasher M, et al. A phase I\/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. J Clin Oncol. 37:TPS2646\u2013TPS2646. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS2646.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2646"},{"key":"2694_CR262","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005267","author":"AW Tolcher","year":"2023","unstructured":"Tolcher AW, et al. Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-\u03b2-trap bifunctional antibody, in patients with advanced solid tumors. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005267.","journal-title":"J Immunother Cancer"},{"key":"2694_CR263","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1200\/JCO.2022.40.16_suppl.2651","volume":"40","author":"M McKean","year":"2022","unstructured":"McKean M, et al. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent\/advanced solid tumors. J Clin Oncol. 2022;40:2651\u20132651. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2651.","journal-title":"J Clin Oncol"},{"key":"2694_CR264","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s1470-2045(25)00709-0","volume":"27","author":"R Dummer","year":"2026","unstructured":"Dummer R, et al. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026;27:327\u201339. https:\/\/doi.org\/10.1016\/s1470-2045(25)00709-0.","journal-title":"Lancet Oncol"},{"key":"2694_CR265","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14:466. https:\/\/doi.org\/10.1038\/s41419-023-05961-3.","journal-title":"Cell Death Dis"},{"key":"2694_CR266","doi-asserted-by":"publisher","first-page":"115688","DOI":"10.1016\/j.ejca.2025.115688","volume":"227","author":"TJ Hieken","year":"2025","unstructured":"Hieken TJ, et al. NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma. Eur J Cancer. 2025;227:115688. https:\/\/doi.org\/10.1016\/j.ejca.2025.115688.","journal-title":"Eur J Cancer"},{"key":"2694_CR267","doi-asserted-by":"publisher","first-page":"e001037","DOI":"10.1136\/bmjonc-2025-001037","volume":"5","author":"ES Zhang","year":"2026","unstructured":"Zhang ES, Osipenko L, Hickman JA. Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors. BMJ Oncol. 2026;5:e001037. https:\/\/doi.org\/10.1136\/bmjonc-2025-001037.","journal-title":"BMJ Oncol"},{"key":"2694_CR268","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/abt\/tbad029","volume":"7","author":"S Wang","year":"2024","unstructured":"Wang S, et al. CD80-Fc fusion protein as a potential cancer immunotherapy strategy. Antib Ther. 2024;7:28\u201336. https:\/\/doi.org\/10.1093\/abt\/tbad029.","journal-title":"Antib Ther"},{"key":"2694_CR269","doi-asserted-by":"publisher","first-page":"A767","DOI":"10.1136\/jitc-2022-SITC2022.0735","volume":"10","author":"M Johnson","year":"2022","unstructured":"Johnson M, et al. 735 A phase 1\/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti\u2013PD-1) in patients with advanced solid tumors: initial dose-escalation results. J Immunother Cancer. 2022;10:A767\u20138. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0735.","journal-title":"J Immunother Cancer"},{"key":"2694_CR270","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","volume":"39","author":"S Jang","year":"2021","unstructured":"Jang S, et al. Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021;39:2631\u20132631. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2631.","journal-title":"J Clin Oncol"},{"key":"2694_CR271","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004424","author":"C Aggarwal","year":"2022","unstructured":"Aggarwal C, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004424.","journal-title":"J Immunother Cancer"},{"key":"2694_CR272","doi-asserted-by":"publisher","first-page":"TPS3105-TPS3105","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3105","volume":"34","author":"AW Tolcher","year":"2016","unstructured":"Tolcher AW, et al. Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. J Clin Oncol. 2016;34:TPS3105\u2013TPS3105. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.TPS3105.","journal-title":"J Clin Oncol"},{"key":"2694_CR273","doi-asserted-by":"publisher","first-page":"TPS2601-TPS2601","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2601","volume":"36","author":"S Shankar","year":"2018","unstructured":"Shankar S, et al. A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors. J Clin Oncol. 2018;36:TPS2601\u2013TPS2601. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS2601.","journal-title":"J Clin Oncol"},{"key":"2694_CR274","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, et al. Immune checkpoint of B7\u2013H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15:153. https:\/\/doi.org\/10.1186\/s13045-022-01364-7.","journal-title":"J Hematol Oncol"},{"key":"2694_CR275","doi-asserted-by":"publisher","first-page":"A018-PR014-A018","DOI":"10.1158\/1538-7445.Pediatric25-a018-pr014","volume":"85","author":"R Epperly","year":"2025","unstructured":"Epperly R, et al. Abstract A018-PR014: B7-H3-CAR T cells expressing 41BB ligand for pediatric solid tumors: preliminary results of a phase 1 study. Cancer Res. 2025;85:A018-PR014-A018-PR014. https:\/\/doi.org\/10.1158\/1538-7445.Pediatric25-a018-pr014.","journal-title":"Cancer Res"},{"key":"2694_CR276","doi-asserted-by":"publisher","first-page":"10011","DOI":"10.1200\/JCO.2022.40.16_suppl.10011","volume":"40","author":"NR Pinto","year":"2022","unstructured":"Pinto NR, et al. STRIVE-02: a first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed\/refractory solid tumors. J Clin Oncol. 2022;40:10011\u201310011. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.10011.","journal-title":"J Clin Oncol"},{"key":"2694_CR277","doi-asserted-by":"publisher","first-page":"TPS3157-TPS3157","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3157","volume":"43","author":"T Kogawa","year":"2025","unstructured":"Kogawa T, et al. IDeate-PanTumor02: a phase 1b\/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors. J Clin Oncol. 2025;43:TPS3157\u2013TPS3157. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS3157.","journal-title":"J Clin Oncol"},{"key":"2694_CR278","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.1016\/j.annonc.2025.08.1586","volume":"36","author":"Y Guo","year":"2025","unstructured":"Guo Y, et al. 1017eTiP A phase II trial of DB-1311\/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305\/BNT325 (TROP2 ADC) in advanced\/metastatic solid tumors. Ann Oncol. 2025;36:S621. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1586.","journal-title":"Ann Oncol"},{"key":"2694_CR279","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00011-016-0995-1","volume":"66","author":"H Su","year":"2017","unstructured":"Su H, Na N, Zhang X, Zhao Y. The biological function and significance of CD74 in immune diseases. Inflamm Res. 2017;66:209\u201316. https:\/\/doi.org\/10.1007\/s00011-016-0995-1.","journal-title":"Inflamm Res"},{"key":"2694_CR280","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/s2352-3026(21)00271-4","volume":"8","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8:e808\u201317. https:\/\/doi.org\/10.1016\/s2352-3026(21)00271-4.","journal-title":"Lancet Haematol"},{"key":"2694_CR281","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131:49\u201357. https:\/\/doi.org\/10.1182\/blood-2017-06-741041.","journal-title":"Blood"},{"key":"2694_CR282","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.Ccr-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal NH, et al. Results from an integrated safety analysis of Urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23:1929\u201336. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1272.","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02694-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:36:11Z","timestamp":1786595771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02694-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":282,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02694-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"196"}}